By Franklin Fuller, Machine Learning Engineer

We are thrilled to announce the latest addition to our Digital Twin Generator (DTG) suite for neurodegenerative diseases: Huntington's disease (HD). We also have DTGs for Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia.

HD is a devastating, progressive neurological disorder that reaches beyond the 41,000 Americans it directly affects, disrupting the lives of their families, dependents, and caretakers. The disease causes behavioral changes, cognitive decline, and physical disability. HD is inherited through a mutation to the huntingtin (HTT) gene and is a dominant mutation, making it very likely to pass on to children.

Despite advances in genetic testing that allow for early diagnosis, there is currently no treatment to halt or reverse the disease's ultimately fatal course. The rarity of the disease coupled with its slow progression of symptoms make it difficult to recruit enough participants for clinical trials, which in turn makes it difficult to have enough statistical power to determine if the experimental treatment is working.

The HD DTG 1.0 released today can predict key endpoints commonly used in HD clinical trials. Our regulatory-qualified AI-powered method can be used to either run highly powered trials without increasing sample sizes or faster trials with smaller control arms. A detailed specification sheet outlining the training data used and the predictive performance metrics of our HD DTG 1.0 is available to download on our website.

With the launch of HD DTG 1.0, we hope to bring attention to the unmet clinical needs of HD and aid in the acceleration of therapeutic development.

If you're interested in learning how to incorporate our HD DTG 1.0 into your upcoming clinical trials, reach out to us today.